HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High
HeartFlow CFO Vikram Verghese sold 33,416 shares for $1.7M under a pre-arranged plan. Post-sale, he holds 221,143 shares. HeartFlow's stock rose 59% in 12 months, with Q2 revenue up 48% YoY to $64.1M. The company raised 2026 guidance and reported 83% gross margin.
How this was made
The 30-second read
Why it matters
The CFO's insider sale provides fresh data on insider sentiment but is unlikely to drive major price moves.
Market read
New Form 4 filing reveals insider sell‑off; modest impact expected.
What to watch
The CFO retains a sizable stake, indicating continued alignment with shareholders.
Background
HeartFlow is a medical‑technology company using AI for cardiac imaging, recently reporting strong revenue growth and a 52‑week high.
Ticker impact
CFO Vikram Verghese sold 33,416 shares for $1.7M via a pre‑arranged Rule 10b5‑1 plan, reducing his stake to 221,143 shares.
Potential modest downward pressure as market digests the sale.
Sale size is modest relative to market cap; executed under a 10b5‑1 plan, so likely not material.
Market effects
Insider activity in med‑tech may be watched by peers but no direct sector impact.
US biotech/med‑tech investors may note the sale.
Limited to HeartFlow and its investors.
Counterpoint
The sale could be a routine liquidity event; investors might ignore it.
Key entities
- ExecutiveVikram Verghese
Chief Financial Officer of HeartFlow
